On June 19, the House of Representatives' Energy & Commerce Subcommittee on Health marked up the MD-CARE Act and voted to advance the bill!
They did it again! The Bormann and Jensen families hosted fundraisers over the Memorial Day weekend and raised more than $34,000 for MDF!
Isis Pharmaceuticals, Inc. announced today that it has launched a Phase 1 clinical trial for ISIS-DMPKRX. ISIS-DMPKRX is designed to reduce the production of toxic dystrophia myotonic-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).